| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.029 | 0.9 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |